➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Colorcon
Express Scripts
Merck
Johnson and Johnson

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RUCAPARIB CAMSYLATE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Rucaparib Camsylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02740712 Pharmacokinetic Drug-Drug Interaction Study of Rucaparib Recruiting Clovis Oncology, Inc. Phase 1 2016-03-01 The purpose of this study is to assess pharmacokinetic concentrations of multiple probes alone followed by assessment of the same drug pharmacokinetic concentrations when the patient has steady-state exposure to rucaparib followed by cycle-by-cycle treatment with rucaparib continuing until disease progression or other reason for discontinuation.
NCT03442556 Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency Not yet recruiting National Cancer Institute (NCI) Phase 2 2018-05-15 This phase II trial studies how well docetaxel, carboplatin, and rucaparib camsylate work in treating patients with castration resistant prostate cancer with homologous recombination deoxyribonucleic acid (DNA) repair deficiency that has spread to other places in the body. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving induction docetaxel and carboplatin followed by maintenance rucaparib camsylate may work better in treating patients with castration resistant prostate cancer.
NCT03442556 Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency Not yet recruiting University of Washington Phase 2 2018-05-15 This phase II trial studies how well docetaxel, carboplatin, and rucaparib camsylate work in treating patients with castration resistant prostate cancer with homologous recombination deoxyribonucleic acid (DNA) repair deficiency that has spread to other places in the body. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving induction docetaxel and carboplatin followed by maintenance rucaparib camsylate may work better in treating patients with castration resistant prostate cancer.
NCT03521037 Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor Recruiting Clovis Oncology, Inc. Phase 1 2018-03-31 Phase 1, open-label, parallel group, PK, safety and tolerability study in patients with an advanced solid tumor and either normal hepatic function (Group 1, n = 8) or moderate hepatic impairment (Group 2, n = 8) according to the NCI-ODWG criteria. Patients in Group 1 and Group 2 may be enrolled in parallel, with preferential enrollment of Group 2 patients before Group 1 patients. The study will consist of 2 parts: a single-dose PK part (Part I) and a continuous rucaparib treatment part (Part II).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Rucaparib Camsylate

Condition Name

Condition Name for Rucaparib Camsylate
Intervention Trials
Neoplasms 2
BRCA1 Gene Mutation 2
Castration-Resistant Prostate Carcinoma 2
BRCA2 Gene Mutation 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Rucaparib Camsylate
Intervention Trials
Prostatic Neoplasms 2
Carcinoma 2
Adenocarcinoma 2
Carcinosarcoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Rucaparib Camsylate

Trials by Country

Trials by Country for Rucaparib Camsylate
Location Trials
Poland 3
United States 2
Czechia 1
United Kingdom 1
Slovakia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Rucaparib Camsylate
Location Trials
Ohio 1
Washington 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Rucaparib Camsylate

Clinical Trial Phase

Clinical Trial Phase for Rucaparib Camsylate
Clinical Trial Phase Trials
Phase 3 1
Phase 2 2
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Rucaparib Camsylate
Clinical Trial Phase Trials
Not yet recruiting 3
Recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Rucaparib Camsylate

Sponsor Name

Sponsor Name for Rucaparib Camsylate
Sponsor Trials
Clovis Oncology, Inc. 4
National Cancer Institute (NCI) 2
Alliance for Clinical Trials in Oncology 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Rucaparib Camsylate
Sponsor Trials
Industry 5
Other 3
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Medtronic
McKinsey
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.